Targeting alternative splicing in cancer immunotherapy

Abstract

Tumor immunotherapy has made great progress in cancer treatment but still faces several challenges, such as a limited number of targetable antigens and varying responses among patients. Alternative splicing (AS) is an essential process for the maturation of nearly all mammalian mRNAs. Recent studies show that AS contributes to expanding cancer-specific antigens and modulating immunogenicity, making it a promising solution to the above challenges. The organoid technology preserves the individual immune microenvironment and reduces the time/economic costs of the experiment model, facilitating the development of splicing-based immunotherapy. Here, we summarize three critical roles of AS in immunotherapy: resources for generating neoantigens, targets for immune-therapeutic modulation, and biomarkers to guide immunotherapy options. Subsequently, we highlight the benefits of adopting organoids to develop AS-based immunotherapies. Finally, we discuss the current challenges in studying AS-based immunotherapy in terms of existing bioinformatics algorithms and biological technologies.

The Many Roads from Alternative Splicing to Cancer: Molecular Mechanisms Involving Driver Genes

“…These examples highlight the significant potential for developing targeted therapies that exploit alternative splicing mechanisms to improve cancer treatment outcomes. Actually, the pharmacological correction of splicing errors is a promising possibility and some compounds are in advanced preclinical stages [ 187 , 188 , 189 , 190 ].…”